Aim: Expanding RAS analyses beyond KRAS exon 2 is important in selecting patients ( pts) for pmab treatment. Here we present prespecified subgroup analyses from a phase 3 randomised second-line pmab + FOLFIRI vs FOLFIRI study in metastatic colorectal cancer (mCRC) pts. Methods: Progression-free (PFS) and overall survival (OS) were co-primary endpoints. Conclusions: Consistent PFS benefits were observed across all subgroups in pts with RAS WT mCRC receiving second-line pmab + FOLFIRI vs FOLFIRI alone.
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